Future research should aim to elucidate the intricate balance of pro-tumorigenic and anti-tumorigenic effects mediated by the IL-33/ST2 axis and to focus on how to harness this knowledge to improve the management of breast cancer. This evidence concerns the gene IL1RL1 and breast carcinoma.